<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582608</url>
  </required_header>
  <id_info>
    <org_study_id>00-066</org_study_id>
    <nct_id>NCT00582608</nct_id>
  </id_info>
  <brief_title>Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9</brief_title>
  <official_title>Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in
      finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten
      themselves to bacteria and viruses. They can stimulate white cells and blood proteins to kill
      tumors. The antibody 8H9 was made from mouse white cells. The white cells that secrete this
      antibody have been made to live for ever. They manufacture large amounts of 8H9 for patient
      use. Although other monoclonal antibodies have been safely tested in people, the antibody 8H9
      has never been given to a human patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test if intravenous injections of iodine-131 labeled murine monoclonal antibody 8H9 can
      detect primary and metastatic solid tumors. A total of 60 patients will be accrued over a
      period of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual
  </why_stopped>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Toxicity is Measured by the Total Number of Participants Affected</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and toxicity is measured by the total number of participants affected. Please see the adverse event table for the specifics for this protocol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>CNS Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>131I-8H9 and 8H9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of `20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131I-8H9</intervention_name>
    <description>This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]</description>
    <arm_group_label>131I-8H9 and 8H9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8H9</intervention_name>
    <description>administration of 50mg/1.73m^2 of unlabeled 8H9.</description>
    <arm_group_label>131I-8H9 and 8H9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of pediatric/adolescent solid tumor (including neuroblastoma,
             rhabdomyosarcoma, Ewing's/PNET, osteosarcoma, brain tumors, desmoplastic small round
             cell tumor (DSRT) and other tumors that are 8H9-positive) confirmed by the MSKCC
             Department of Pathology.

          -  Patient must have either recurrent disease or have &lt;20% chance of long term
             disease-free survival.

          -  Patient must be at least 1 year old. Age can range from 1-50 years of age.

          -  Patients should have measurable or evaluable disease. For tumor types that are known
             to be 8H9-positive, patients can be imaged after the diagnosis is made, prior to
             definitive surgery or surgery to confirm tumor recurrence.

          -  Tumor tissue is or will be available for 8H9 immunostaining. For patients with
             tumor-types known to be 8H9-positive, surgical samples obtained after 131I- 8H9
             imaging will be immunostained to confirm 8H9-reactivity. These tumor types include:
             neuroblastoma, rhabdomyosarcoma, osteosarcoma, DSRT, Ewing's Sarcoma/PNET), brain
             tumors (glioblastoma multiforme, mixed glioma, astrocytoma, ependymoma,
             medulloblastoma, schwannoma., meningioma).

          -  If frozen tumor tissue is unavailable, and if bone marrow involvement is demonstrated
             by histology, 8H9 immunostaining by immunofluorescence will be carried out on
             patient's bone marrow. In this case, patients will be eligible for study if bone
             marrow 8H9 immunostaining is positive.

        Exclusion Criteria:

          -  Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary,
             gastrointestinal, and neurologic system toxicity should all be less than grade 2.
             Patients with stable neurological deficits (because of their brain tumor) are not
             excluded. Patients with &lt;= 3 hearing loss are not excluded.

          -  Clinically apparent infections.

          -  History of allergy to iodine or mouse proteins.

          -  Patients previously treated with mouse monoclonal antibodies are not eligible unless
             they have no circulating HAMA.

          -  Pregnant women are excluded for fear of danger to the fetus. Therefore negative
             pregnancy test is required for all women of child-bearing age, and appropriate
             contraception is used during the study period.

          -  Patient's own tumor is negative by 8H9 immunostaining.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakeel Modak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MAB 131-I LABELED 8H9</title>
          <description>MAB 131-I LABELED 8H9: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled 8H9.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of accrual</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MAB 131-I LABELED 8H9</title>
          <description>MAB 131-I LABELED 8H9: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled 8H9.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Toxicity is Measured by the Total Number of Participants Affected</title>
        <description>Safety and toxicity is measured by the total number of participants affected. Please see the adverse event table for the specifics for this protocol.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MAB 131-I LABELED 8H9</title>
            <description>MAB 131-I LABELED 8H9: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled 8H9.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity is Measured by the Total Number of Participants Affected</title>
          <description>Safety and toxicity is measured by the total number of participants affected. Please see the adverse event table for the specifics for this protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MAB 131-I LABELED 8H9</title>
          <description>MAB 131-I LABELED 8H9: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled 8H9.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Technical problems led to unreliable and uninterpretable data. Therefore, there is no data to report under Outcome Measures. Due to lack of patients accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Shakeel Modak</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-7623</phone>
      <email>modaks@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

